The therapeutic use of this medication is primarily relevant for managing severe symptoms related to systemic imbalance in critically ill patients. It is commonly used across conditions associated with acute or disruptive episodes, including shock syndrome, severe hypotension, and acute cardiac pump failure.

---

Treating Acute Circulatory Failure and Shock Syndromes

This medication is generally used to provide supportive relief when symptoms become temporarily overwhelming in the most critical clinical settings, targeting conditions associated with acute or disruptive episodes like shock syndrome (e.g., from severe heart attack, infection, or trauma) where the body's circulation is compromised. This therapy contributes to maintaining stability when symptoms are more noticeable, addressing the profound systemic imbalance that affects circulatory function.

---

Managing Severe Hypotension

The core therapeutic application is relevant for easing the symptomatic effects of severe hypotension, a dangerously low blood pressure that creates noticeable physiological strain. It offers supportive relief when symptoms interfere with routine activities by supporting blood pressure levels, which is relevant in contexts involving heightened systemic burden.

---

Quick Fact: Support for Symptoms Linked to Organ Stress The medication assists with managing the symptom cluster associated with acute cardiac pump failure or states of low cardiac output, helping to ease the overall symptom load that results from poor blood distribution.

Regulatory References

1. NIH DailyMed service

Who Can and Cannot Use Dopamine?

Regulatory documents establish specific rules for patient eligibility concerning the use of Dopamine injection, primarily defined by contraindications and necessary pre-conditions.

---

Populations That Must Not Use Dopamine

Dopamine is formally contraindicated (must not be used) in patients who have a diagnosis of pheochromocytoma (a tumor of the adrenal gland) or who have pre-existing, uncorrected tachyarrhythmias (rapid, irregular heart rhythms) such as ventricular fibrillation.

---

Eligibility Restrictions and Special Considerations

Official labeling requires that underlying conditions such as hypovolemia (low blood volume), acidosis, and hypoxia must be addressed and corrected prior to, or concurrently with, the initiation of Dopamine therapy. Individuals with a known severe hypersensitivity to sulfites (the formulation contains sodium metabisulfite) should not use this medicine due to the risk of severe allergic reactions.

For pediatric patients, the safety and efficacy of the drug have not been fully established, limiting its eligibility. Additionally, use in patients with occlusive vascular disease requires careful monitoring for signs of peripheral ischemia.

The official regulatory profile for Dopamine (Dopamine Hydrochloride) establishes specific restrictions and cautions for co-administration with other substances, primarily focused on metabolic interference, pharmacodynamic potentiation, and chemical instability.

Official Interaction Statements

• Monoamine Oxidase Inhibitors (MAOIs): Co-administration is formally classified as a pharmacokinetic interaction. Because Dopamine is metabolized by MAO, inhibition of this enzyme prolongs and potentiates Dopamine's effects, carrying a documented risk of severe hypertension and cardiac arrhythmia.
• Tricyclic Antidepressants (TCAs): Concomitant use with this class of medicines is officially noted to potentiate the cardiovascular effects of Dopamine, such as hypertension.
• Anesthetics: Halogenated hydrocarbon anesthetics (e.g., desflurane, isoflurane) and Cyclopropane are documented as potentially sensitizing the myocardium to the action of Dopamine, increasing the risk of ventricular arrhythmias.
• Pharmacodynamic Antagonism: The cardiac effects are antagonized by beta-adrenergic blocking agents, and the peripheral vasoconstriction caused by higher rates of infusion is antagonized by alpha-adrenergic blocking agents.

Interaction-Related Restrictions and Timing Rules

• Chemical Incompatibility: Simultaneous administration through the same infusion set is prohibited with Sodium Bicarbonate or any other alkalinizing substances, as Dopamine is officially documented to be chemically inactivated in alkaline solutions.
• Blood: Simultaneous administration through the same infusion set should be avoided due to the documented risk of pseudoagglutination of red cells.
• Diuretic Agents: Concurrent administration is officially noted to produce an additive or potentiating effect on urine flow.

The totality of the official regulatory data defines the product’s interaction structure by classifying agents that alter its metabolic clearance and those that reinforce or oppose its core hemodynamic activity. The profile includes mandatory procedural constraints regarding incompatible intravenous mixing solutions.

️ How Дофамин Works: A Mechanism of Action

The mechanism of Dopamine Hydrochloride is characterized by a precise, concentration-dependent agonism that sequentially engages multiple receptors to produce changes in the rate and force of myocardial contraction and systemic vascular resistance.

---

Tiered Agonism and Receptor Selectivity

Dopamine acts as an agonist for dopaminergic (mathbfD1) and adrenergic (mathbfbeta1 and mathbfalpha1) receptors. The interaction shifts across these targets as the drug's concentration increases in the bloodstream. This modulation produces changes in systems where a rapid, targeted adjustment of sympathetic signaling is required to shape the physiological response.

---

️ Myocardial Force Enhancement (beta1 Pathway)

The drug's interaction with mathbfbeta1 receptors in the heart initiates a molecular cascade that increases intracellular calcium, leading to enhanced myocardial contractility and rate. This mechanism results in a positive inotropic effect that contributes to an increase in the force of myocardial contraction and Cardiac Output.

---

Dual Vascular Tone Modulation (alpha1 and mathbfD1 Pathways)

Dopamine engages two distinct vascular pathways: mathbfalpha1 agonism causes widespread smooth muscle contraction to increase Systemic Vascular Resistance (SVR); conversely, mathbfD1 agonism promotes vasodilation in key regional circulations. This dual effect helps modulate systemic blood pressure while resulting in increased localized perfusion.

How to Use Дофамин (Dopamine Hydrochloride)

The administration of Dopamine Hydrochloride is confined to a continuous intravenous infusion in a highly monitored setting, such as an intensive care unit. This approach is utilized due to the drug’s specialized nature and requirements for precise flow control.

---

Administration Protocol and Preparation

The medication is delivered into a large vein using an infusion pump to ensure the controlled delivery required for the continuous infusion regimen. Before administration, the concentrate solution is diluted with an approved solution, such as 0.9% Sodium Chloride or 5% Dextrose Injection. The solution is not mixed with alkaline substances to prevent inactivation of the active ingredient. Furthermore, pre-existing conditions such as hypovolemia, acidosis, and hypoxia are typically addressed prior to initiating the infusion.

---

Dosing and Titration

Dosing is individualized and begins with a starting rate typically ranging from 2 to 5 mcg/kg/minute for both adult and pediatric patients. The rate of the infusion is then titrated (adjusted) in small increments by the healthcare provider according to the patient’s real-time physiological response. Most patients are maintained at rates less than 20 mcg/kg/minute. For patients who have recently received MAO inhibitors, the initial Dopamine dose is adjusted to no more than one-tenth (1/10) of the usual starting dose. Upon completion of therapy, the infusion rate is gradually reduced (tapered) rather than abruptly stopped.

Research evidence / Overview of studies for Дофамин

Evidence for use in Hemodynamic Imbalances in Shock Syndrome

Dopamine was studied for its use in critically ill adult patients who have low blood pressure due to different types of shock, which are conditions associated with acute or disruptive episodes. Researchers used large, randomized controlled trials (RCTs) and observational cohorts to examine short-term patient survival, typically all-cause mortality at 28 days, and outcomes related to systemic or functional imbalance, like achieving a stable blood pressure.

Research highlights changes measured during the study period, and comparative studies reported that measurements of 28-day survival were observed in a similar range when dopamine was studied alongside other agents. However, certain trials described that patients receiving dopamine was associated with a higher frequency of abnormal heart rhythms, known as arrhythmias. The evidence includes reported measurements of heart rhythms in these critically ill populations.

Evidence for use in Symptomatic Bradycardia

Dopamine was studied for patients experiencing symptomatic bradycardia (a heart rate that is too slow and causing symptoms), which conditions involving periods of heightened symptoms. Studies in this area primarily used clinical series and observational settings to evaluate patient responses. These studies monitored outcomes reflecting daily functioning or activity level and acute changes in heart rate and blood pressure measurements.

Studies reported how symptoms evolved in the observed populations, noting that studies reported measurements of heart rate and blood pressure following administration. Specific studies focusing on this use against a non-active treatment are less common. Findings describe patterns observed in protocols where dopamine is used if initial treatment with other drugs is not successful.

Evidence for Low-Dose Use (Perfusion and Urine Output)

Studies reported inconsistent measurements across different populations for low-dose use. The research highlights changes measured during the study period, showing that low-dose dopamine was observed in some studies where temporary increases in urine output were noted. However, multiple analyses reported that measurements of outcomes such as the patient's need for kidney dialysis or long-term survival were inconsistent or not sustained.

What is Still Uncertain About Дофамин Research

Long-term data following dopamine administration in the ICU setting are not extensively available. Follow-up durations were limited primarily to the first 28 days. Data for certain groups remain insufficient, especially regarding pregnancy-related populations or individuals with certain chronic underlying conditions. Certainty remains low regarding the optimal time to administer the drug in treatment protocols. The evidence highlights what is known—and what is still uncertain—about its use in varied and complex critical care settings.

Key Studies & References

1. Adult Bradycardia With a Pulse Algorithm (ACLS Guidelines)

Common questions about Дофамин (FAQ)

---

Q: What is the maximum recommended infusion rate for Dopamine?

Official product information notes that dosage adjustments can be made up to a maximum rate of 50 mcg/kg/minute for adult and pediatric patients. Dosing is highly individualized and is adjusted by the healthcare provider based on the patient's condition and real-time physiological response, as continuous monitoring is required.

---

Q: What are the signs of Dopamine extravasation and how serious is it?

Extravasation is the leakage of the medicine from the vein into surrounding tissue. Official product information cautions that this can lead to tissue necrosis (tissue death) and sloughing. The administration site is continuously monitored by the healthcare team for any signs of leakage to prevent this potentially serious reaction.

---

Q: How long is the diluted Dopamine solution stable?

The diluted solution is stated to be stable for 24 hours when stored at 25 C. However, due to the risk of bacterial contamination, official guidance indicates the solution should be used immediately after preparation unless the dilution was done under strictly controlled, sterile (aseptic) conditions.

---

Q: How does Dopamine interact with Tricyclic Antidepressants (TCAs)?

Regulatory documents note that Tricyclic Antidepressants may potentiate (increase the effect of) the pressor response to Dopamine, which means it can raise blood pressure more than expected. Due to this potential drug interaction, the patient's blood pressure requires careful and continuous monitoring by the healthcare team.

---

Q: What are the signs a patient is experiencing a severe allergic reaction to the sulfites in the injection?

The sulfite ingredient in the formulation can cause allergic-type reactions. These reactions range from less severe asthmatic episodes to potentially life-threatening anaphylactic symptoms. People with pre-existing asthma may be more susceptible, and healthcare providers monitor for signs of hypersensitivity during administration.

---

Q: If a patient is pregnant, can they still receive Dopamine for shock?

Official safety information notes that while there is no data on the effects of Dopamine specifically in pregnant women, delaying life-sustaining treatment for shock is associated with increased risks to both the mother and the fetus. In acute, life-threatening scenarios, life-sustaining treatment is generally not withheld due to concerns about the drug’s potential effects on the fetus.

How to Store and Dispose of Dopamine Hydrochloride Injection

Dopamine Hydrochloride Injection must be stored at Controlled Room Temperature, defined as 20^circC to 25^circC (68^circF to 77^circF). The product must be protected from freezing and avoid excessive heat. Vials or ampoules must be kept in the outer carton to protect from light and stored out of the sight and reach of children.

Once diluted, the solution is stable for 24 hours. Before use, the solution must be visually inspected and must not be administered if discolored or if particulate matter is present. As the product is supplied in single-dose containers, any unused portion must be discarded according to local pharmaceutical waste regulations, and environmental release (such as emptying into drains) must be avoided.